Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Treasury Shares (2022 - 2025)

Lyra Therapeutics has reported Treasury Shares over the past 4 years, most recently at $51814.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $51814.0 for Q4 2025, up 20.88% from a year ago — trailing twelve months through Dec 2025 was $51814.0 (up 20.88% YoY), and the annual figure for FY2025 was $51814.0, up 20.88%.
  • Treasury Shares for Q4 2025 was $51814.0 at Lyra Therapeutics, down from $58882.0 in the prior quarter.
  • Over the last five years, Treasury Shares for LYRA hit a ceiling of $4.7 million in Q1 2025 and a floor of $28212.0 in Q4 2022.
  • Median Treasury Shares over the past 4 years was $95426.0 (2023), compared with a mean of $548418.8.
  • Biggest five-year swings in Treasury Shares: surged 588.08% in 2023 and later crashed 93.21% in 2025.
  • Lyra Therapeutics' Treasury Shares stood at $28212.0 in 2022, then soared by 272.35% to $105048.0 in 2023, then plummeted by 59.19% to $42865.0 in 2024, then rose by 20.88% to $51814.0 in 2025.
  • The last three reported values for Treasury Shares were $51814.0 (Q4 2025), $58882.0 (Q3 2025), and $85804.0 (Q2 2025) per Business Quant data.